Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence

Rossing, Peter; Caramori, Luiza M; Chan, Juliana C. N; Earley, Amy; de Boer, Ian H.

Kidney int; 102 (5), 2022

The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (CKD) represents a focused update of the KDIGO 2020 guideline on the topic. The guideline targets a broad audience of clinicians treating people with diabetes and CKD. ...

Insuficiencia Renal Crónica/tratamiento farmacológico, Diabetes Mellitus Tipo 2/prevención & control, Automanejo, Control Glucémico, Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico, Antagonistas de Receptores de Angiotensina/uso terapéutico, Inhibidores del Cotransportador de Sodio-Glucosa 2/uso terapéutico

Texto completo

Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease

Cheung, Alfred; Chag, Tara; Cushman, William; Furth, Susan; Hou, Fan; Ix, Joachim; Knoll, Gregory; Muntner, Paul; Pecoits-Filho, Roberto; Sarnak, Mark; Tobe, Sheldon; Tomson, Charles; Lytvyn, Lyubov; Craig, Jonathan; Tunnicliffe, David; Howell, Martin; Tnoelli, Marcelo; Cheung, Michael; Earley, Amy; Mann, Johannes.

Kidney int; 99 (3), 2021

The Kidney Disease: Improving Global Outcomes (KDIGO) 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease for patients not receiving dialysis represents an update to the KDIGO 2012 guideline on this topic. Development of this guideline update followed a rigorou...

Insuficiencia Renal Crónica/prevención & control, Monitoreo Ambulatorio de la Presión Arterial/normas, Diabetes Mellitus/prevención & control, Ejercicio Físico, Estilo de Vida Saludable, Presión Sanguínea/efectos de los fármacos, Antihipertensivos/uso terapéutico, Receptores de Trasplantes

Texto completo

KDOQI Clinical Practice Guideline for vascular access: 2019 update

Lok, Charmaine E; Huber, Thomas S; Lee, Timmy; Shenoy, Surendra; Yevzlin, Alexander S; Abreo, Kenneth; Allon, Michael; Asif, Arif; Astor, Brad C; Glickman, Marc H; Graham, Janet; Moist, Louise M; Rajan, Dheeraj K; Roberts, Cynthia; Vachharajani, Tushar J; Valentini, Rudolph P.

Am. j. kidney dis; 75 (4 supl. 3), 2020

The National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative (KDOQI) has provided evidencebased guidelines for hemodialysis vascular access since 1996. Since the last update in 2006, there has been a great accumulation of new evidence and sophistication in the guidelines process. The 201...

Medicina Basada en la Evidencia, Soluciones para Hemodiálisis/normas, Dispositivos de Acceso Vascular, Insuficiencia Renal Crónica/terapia

Texto completo

KDOQI clinical practice guideline for hemodialysis adequacy: 2015 update

Am. j. kidney dis; 66 (5), 2015

The National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDOQI) has provided evidence-based guidelines for all stages of chronic kidney disease (CKD) and related complications since 1997. The 2015 update of the KDOQI Clinical Practice Guideline for Hemodialysis Adequacy is intended to...

Insuficiencia Renal Crónica/terapia, Diálisis Renal/normas, Hemofiltración/normas, Factores de Tiempo, Enfoque GRADE

Texto completo

Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: a clinical practice guideline from the American College of Physicians

Qaseem, A; Hopkins, RH Jr; Sweet, D. E; Starkey, M; Shekelle, P.

Ann. intern. med; 159 (12), 2013

DESCRIPTION: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the screening, monitoring, and treatment of adults with stage 1 to 3 chronic kidney disease. METHODS: This guideline is based on a systematic evidence review eval...

Insuficiencia Renal Crónica/diagnóstico, Insuficiencia Renal Crónica/tratamiento farmacológico, Progresión de la Enfermedad, Triaje, Antagonistas de Receptores de Angiotensina/uso terapéutico, Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico, Antihipertensivos/uso terapéutico, Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico, Hipolipemiantes/uso terapéutico, Gemfibrozilo/uso terapéutico, Enfermedades Asintomáticas, Quimioterapia Combinada, Enfoque GRADE

Texto completo